Amgen Buys deCODE Genetics For $415M

THOUSAND OAKS, Calif. (AP) -- Biotech drug maker Amgen is buying human genetics research and analytics company deCODE Genetics for $415 million. DeCODE, based in Reykjavik, Iceland, has discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer "DeCODE Genetics has built a world-class capability in the study of the genetics of human disease. This ...

More:

Amgen Buys deCODE Genetics For $415M

Related Posts

Comments are closed.